A multi-centre comparison of nursing staff time required for the preparation and administration of liposomal amphotericin B and amphotericin B deoxycholate vs. voriconazole

Journal of Clinical Nursing

Volumn 18, Issue 8, 2009, Pages 1168-1179

  Flynn, Elizabeth ^a   Marciniak, Anne ^b   Barbabietola, Giuliana ^c   Oppenheim, Beryl A ^d   Roberts, Craig ^e   Barker, Kenneth ^f  

^a Center for Pharmacy Operations and Designs   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c Ospedale San Giovanni Battista   (Italy)

^d CITY HOSPITAL   (United Kingdom)

^e PFIZER INC   (United States)

^f AUBURN UNIVERSITY   (United States)

Author keywords

Health economics; Infectious diseases; Nurses; Nursing

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; AMPHOTERICIN B-DEOXYCHOLATE; ANTIFUNGAL AGENT; DEOXYCHOLIC ACID; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; COST; DRUG COMBINATION; MULTICENTER STUDY; TIME MANAGEMENT; UNITED KINGDOM;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; COSTS AND COST ANALYSIS; DEOXYCHOLIC ACID; DRUG COMBINATIONS; GREAT BRITAIN; PYRIMIDINES; TIME MANAGEMENT; TRIAZOLES;

EID: 61849177154     PISSN: 09621067     EISSN: 13652702     Source Type: Journal    
DOI: 10.1111/j.1365-2702.2008.02512.x     Document Type: Article

References (31)

1. Alonso M, De Miguel M, Sautua S Baza B (2004) Monitoring the use of new antifungal agents and its budgetary impact. ASHP Summer Meeting 61, P 64D.
2. R). ISMP Canada Safety Bulletin 2, 1 2.
3. Bates DW, Su L, Yu DT, Chertow GM, Seger DL, Gomes DR, Dasbach EJ Platt R (2001) Mortality and costs of acute renal failure associated with amphotericin B therapy [see comment]. Clinical Infectious Diseases 32, 686 693.
4. Bauters TG, Buyle FM, Peleman R Robays H (2005) Antifungal drugs and rational use of antifungals in treating invasive aspergillosis: the role of the hospital pharmacist. Pharmacy World and Science 27, 31 34.
5. Bilalyan LB, Cellana SA Dalton DM (2003) Cost effectiveness of liposomal amphotericin b versus voriconazole in the treatment of invasive aspergillosis. ASHP Midyear Clinical Meeting 38, P-327.
6. Boogaerts M, Winston DJ, Bow EJ, Garber G, Reboli AC, Schwarer AP, Novitzky N, Boehme A, Chwetzoff E De Beule K Itraconazole Neutropenia Study Group (2001) Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Annals of Internal Medicine 135, 412 422.
7. Cagnoni PJ, Walsh TJ, Prendergast MM, Bodensteiner D, Hiemenz S, Greenberg RN, Arndt CA, Schuster M, Seibel N, Yeldandi V Tong KB (2000) Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients [erratum appears in Journal of Clinical Oncology18, 3064]. Journal of Clinical Oncology 18, 2476 2483.
8. Cohen M (1998) Medication Errors with Certain Lipid-Based Drug Products. ISMP Medication Safety Alert Institute for Safe Medication Practices, Warminster, PA.
9. Fischer MA, Solomon DH, Teich JM Avorn J (2003) Conversion from intravenous to oral medications: assessment of a computerized intervention for hospitalized patients. Archives of Internal Medicine 163, 2585 2589.
10. Fleming T, ed 2005) 2005 Red Book. Thomson PDR, Montvale, NJ.
11. Florea NR, Kuti JL, Nightingale CH Nicolaul DP (2004) IV to oral conversion programs for anti-infectives in the United States: prevalence and characteristics. Hospital Pharmacy 39, 1069 1075.
12. Foltyn Smith C Amen RJ (1988) Comparison of seven methods of preparing and administering small-volume injections. American Journal of Hospital Pharmacy 45, 1896 1901.
13. Fromtling RA Castaner J (1996) Voriconazole. Drugs of the Future 21, 266 271.
14. Goodwin SD, Cleary JD, Walawander CA, Taylor JW Grasela TH Jr. (1995) Pretreatment regimens for adverse events related to infusion of amphotericin B. Clinical Infectious Diseases 20, 755 761.
15. Guerrero RM, Nickman NA Jorgenson JA (1996) Work activities before and after implementation of an automated dispensing system. American Journal of Health-System Pharmacy 53, 548 554.
16. Hann IM Prentice HG (2001) Lipid-based amphotericin B: a review of the last 10 years of use. Internation Journal of Antimicrobial Agents 17, 161 169.
17. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. New England Journal of Medicine 347, 408 415.
18. Lewis JS, Boucher HW, Lubowski TJ, Ambegaonkar AJ, Day DL Patterson TF (2005) Cost advantage of voriconazole over amphotericin B deoxycholate for primary treatment of invasive aspergillosis. Pharmacotherapy 25, 839 846.
19. Pedersen CA, Schneider PJ Scheckelhoff DJ (2003) ASHP national survey of pharmacy practice in hospital settings: dispensing and administration - 2002. American Journal of Health-System Pharmacy 60, 52 68.
20. Prentice HG, Hann IM, Herbrecht R, Aoun M, Kvaloy S, Catovsky D, Pinkerton CR, Schey SA, Jacobs F, Oakhill A, Stevens RF, Darbyshire PJ Gibson BE (1997) A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. British Journal of Haematology 98, 711 718.
21. Rapp RP (2004) Changing strategies for the management of invasive fungal infections. Pharmacotherapy 24 (2 Pt. 2 4S 28S.
22. Rotstein C, Laverdiere M, Marciniak A Ali F (2004) An economic evaluation of voriconazole versus amphotericin B for the treatment of invasive aspergillosis in Canada. The Canadian Journal of Infectious Diseases and Medical Microbiology 15, 277 284.
23. Tanner DJ (1984) Cost containment of reconstituted parenteral antibiotics: personnel and supply costs associated with preparation, dispensing, and administration. Reviews of Infectious Diseases 6 (Suppl 4 S924 S937.
24. Tanner DJ Nazarian MQ (1984) Cost containment associated with decreased parenteral antibiotic administration frequencies. American Journal of Medicine 77, 104 111.
25. US Department of Labor, US Bureau of Labor Statistics (2004) National Compensation Survey: Occupational Wages in the United States. Available at: http://www.bls.gov/ncs/ocs/sp/ncbl0727.pdf (accessed 29 May 2007).
26. Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, Pappas P, Seibel N, Greenberg RN, Dummer S, Schuster M Holcenberg JS (1999) Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. New England Journal of Medicine 340, 764 771.
27. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, Yanovich S, Stiff P, Greenberg R, Donowitz G, Schuster M, Reboli A, Wingard J, Arndt C, Reinhardt J, Hadley S, Finberg R, Laverdière M, Perfect J, Garber G, Fioritoni G, Anaissie E, Lee J National Institute of Allergy and Infectious Diseases Mycoses Study Group (2002) Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. New England Journal of Medicine 346, 225 234.
28. Wenzel R, Del Favero A, Kibbler C, Rogers T, Rotstein C, Mauskopf J, Morris S, Schlamm H, Troke P Marciniak A (2005) Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients. Journal of Antimicrobial Chemotherapy 55, 352 361.
29. Wilson K Sullivan M (2004) Preventing medication errors with smart infusion technology. American Journal of Health-System Pharmacy 61, 177 183.
30. Wingard JR, Herbrecht R, Marciniak A Roberts CS (2004) Hospital resource utilization in acute invasive aspergillosis (aia) patients (pts) treated with voriconazole (vor) or amphotericin b (cab). ASH Annual Meeting Abstracts 104, 88.
31. van Zanten AR, Engelfriet PM, van Dillen K, van Veen M, Nuijten MJ Polderman KH (2003) Importance of nondrug costs of intravenous antibiotic therapy. Critical Care 7, R184 R190.